Adlai Pappy
Growth, long only, value

Threshold Pharmaceuticals Presents A Robust Risk/Reward As A Speculative Small-Cap Cancer Investment

While the end of 2013 and the beginning of 2014 saw many speculative pharmaceutical and biotech companies experience immense growth, the recent sector pullback exemplifies the need to select fundamentally strong investments. I have identified Threshold Pharmaceuticals (NASDAQ:THLD) as a stock that traded relatively flat during the past 18 months, but presents an attractive investment in the near and long term.

Threshold Pharmaceuticals was incorporated in 2001, and went public in 2004. THLD is a small-cap pharmaceutical company focused on improving the treatment of various cancers - such as soft-tissues sarcomas (STS), pancreatic cancer, and multiple myeloma - through its therapies, with a unique mechanism of action. The company develops therapies that target the microenvironment of a number...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details